Diligence memo · auto-generated · as of July 2, 2026
Spear Bio Inc.
Spear Bio Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Spear Bio Inc. operates in Biotechnology, based in Woburn.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Spear Bio Inc. has raised $50M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $45M on 2024-07-23.
Most recent recorded round closed around 2024-07-23.
Valuation (modeled)modeled
Provath models Spear Bio Inc. at approximately $392M (range $139M–$591M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.79× the median modeled value of Series C Biotechnology companies in 2022–2024 (111 peers) — value vs value, same stage and era. Within the normal band (79% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 23 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round stepped up 18.8× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 82% of Biotechnology peers (4293 compared).
Modeled value ranks above 80% of those peers.
Closest niche peers: Dianthus Therapeutics, Inc., Satellite Biosciences, Inc., Deepcell, Inc., Ventus Therapeutics U.S., Inc., Morphic Holding, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.